A/Prof Dipti Talaulikar

Associate Professor Dipti Talaulikar is a top clinical haematologist at Icon Cancer Centre Canberra. Her career in haematology began in 2003, when she was an advanced trainee haematology registrar at Canberra Hospital while pursuing post-graduate studies at the Australian National University (ANU). In addition, she holds a graduate certificate in higher education and a PhD degree, where she investigated occult bone marrow involvement in Diffuse Large B-cell lymphoma.

A/Prof Talaulikar has a keen interest in medical leadership, research and clinical trials, which she incorporates into her role as a senior staff specialist at Canberra Hospital and in private practice. She has served as principal investigator and co-investigator of several lymphoma, leukaemia and myeloma trials. Furthermore, she is an Associate Professor of the College of Medicine, Biology and Environment at ANU, where she supports and mentors emerging medical professionals. A/Prof Talaulikar is also a member of leading cancer trial and research groups such as the Australasian Leukaemia & Lymphoma Group (ALLG), Australian Lymphoma Alliance, American Society of Haematology (ASH) and Haematology Society of Australia and New Zealand (HSANZ). Additionally, she serves as a member of the Medical & Scientific Advisory Group (MSAG) of Myeloma Australia and a steering committee member of the Lymphoma and Related Diseases Registry (LaRDR).

A/Prof Talaulikar is a prolific author and has published several clinical research articles and practice guidelines in top-notch publications such as the Journal of Internal Medicine and British Journal of Haematology. Moreover, she presents her work regularly at national and international haematology conferences. As a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA), A/Prof Talaulikar has extensive experience managing a broad range of malignant blood disorders, with a special focus on leukaemia, myeloma, lymphoma and myeloproliferative neoplasms.